EndoCyclic Therapeutics

Executive Summary

EndoCyclic Therapeutics is a clinical-stage biotech company pioneering first-in-class, non-hormonal therapies for women's health and oncology. Its proprietary platform leverages cell-permeating, pH-sensitive peptides that selectively target diseased tissue, enabling localized intracellular activity. The lead candidate, ENDO-205, addresses endometriosis, a condition with limited non-hormonal treatment options that affects millions of women worldwide. By avoiding hormonal side effects, ENDO-205 could offer a safer, more tolerable alternative to current standard-of-care therapies. Beyond endometriosis, the platform holds potential in oncology, where acidic tumor microenvironments can trigger peptide activation. The company is based in Cambridge, MA, and is privately held. With a strong scientific premise and a clear unmet need, EndoCyclic is positioned to attract strategic partnerships and investor interest as it advances toward clinical proof-of-concept.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 trial initiation for ENDO-205 in endometriosis70% success
• H2 2026Presentation of preclinical oncology data at a major medical conference80% success
• 2026Series B financing round to support Phase 1 development50% success